Norlichexanthone
Catalog No: CFN98041
Norlichexanthone has the potential to treat and/or prevent lifestyle-related diseases, including metabolic syndrome, type 2 diabetes, atherosclerosis and cardiovascular diseases.Norlichexanthone has antibacterial and antimalarial activities, it shows strong activity against Bacillus subtilis with IC50 in the range of 1-5uM, it also significantly inhibits the growth of methicillin-resistant Staphylococcus aureus with IC50 of 20.95±1.56uM.
Ginsenoside Rb3
Catalog No: CFN99966
Ginsenoside Rb3 has anti-myocardial ischemia-reperfusion injury, neuroprotective, antidepressant-like, and antioxidant effects, it also possesses the potential of the clinical use in preventing and treating diabetes. Ginsenoside Rb3 significantly attenuates the changes of creatine kinase activity and lactate dehydrogenase activity, exhibits inhibitory effect on TNFα-induced NF-κB transcriptional activity with an IC50 of 8.2 μM in 293T cell lines, it also inhibits the induction of COX-2 and iNOS mRNA.
20(S)-Ginsenoside Rh2
Catalog No: CFN99971
Ginsenoside Rh2 has memory-enhancing ,anti-osteoporosis, antitumor, antidiabetic, antiallergic, and anti-inflammatory effects, it potently protects ischemia-reperfusion brain injury, also inhibits prostaglandin-E_2 synthesis in lipopolysaccharide-stimulated RAW264.7 cells. It can inhibit the tendency of apoptosis, and reverse the impaired β-cell growth potential by modulating Akt/Foxo1/PDX-1 signaling pathway and regulating cell cycle proteins; it suppresses RANKL-induced osteoclast differentiation in vitro and in vivo through the regulation of c-Fos and NFATc1 expressions, not excluding the involvement of NF-κB and ERK.
Ginsenoside Rc
Catalog No: CFN99973
Ginsenoside Rc exhibits anti-diabetic, anti-adipogenic, anticancer and anti-inflammatory activities; it can attenuate inflammatory symptoms of gastritis, hepatitis and arthritis, and it can significantly enhance glucose uptake by inducing ROS generation, which leads to AMPK and p38 MAPK activation. Rc enhances GABA receptorA (GABAA)-mediated ion channel currents (IGABA), it also inhibits the expression of TNF-α and IL-1β.
